JPWO2021030680A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021030680A5 JPWO2021030680A5 JP2022509082A JP2022509082A JPWO2021030680A5 JP WO2021030680 A5 JPWO2021030680 A5 JP WO2021030680A5 JP 2022509082 A JP2022509082 A JP 2022509082A JP 2022509082 A JP2022509082 A JP 2022509082A JP WO2021030680 A5 JPWO2021030680 A5 JP WO2021030680A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- molecule
- domains
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015817A JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962887411P | 2019-08-15 | 2019-08-15 | |
| US62/887,411 | 2019-08-15 | ||
| US201962924435P | 2019-10-22 | 2019-10-22 | |
| US62/924,435 | 2019-10-22 | ||
| US202062978584P | 2020-02-19 | 2020-02-19 | |
| US62/978,584 | 2020-02-19 | ||
| US202063057824P | 2020-07-28 | 2020-07-28 | |
| US63/057,824 | 2020-07-28 | ||
| PCT/US2020/046352 WO2021030680A1 (en) | 2019-08-15 | 2020-08-14 | Multispecific antigen-binding molecules for cell targeting and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015817A Division JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022545647A JP2022545647A (ja) | 2022-10-28 |
| JP2022545647A5 JP2022545647A5 (https=) | 2023-08-10 |
| JPWO2021030680A5 true JPWO2021030680A5 (https=) | 2023-08-10 |
| JP7629906B2 JP7629906B2 (ja) | 2025-02-14 |
Family
ID=72243251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509082A Active JP7629906B2 (ja) | 2019-08-15 | 2020-08-14 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
| JP2025015817A Pending JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015817A Pending JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US12077603B2 (https=) |
| EP (1) | EP4013797A1 (https=) |
| JP (2) | JP7629906B2 (https=) |
| KR (1) | KR20220044821A (https=) |
| CN (2) | CN114302893B (https=) |
| AU (1) | AU2020330063A1 (https=) |
| BR (1) | BR112022002012A2 (https=) |
| CA (1) | CA3147791A1 (https=) |
| IL (1) | IL290299A (https=) |
| MX (1) | MX2022001942A (https=) |
| TW (2) | TW202542199A (https=) |
| WO (1) | WO2021030680A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| LT3353212T (lt) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| MX2022000896A (es) | 2019-07-24 | 2022-02-14 | Regeneron Pharma | Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos. |
| JP2024500409A (ja) | 2020-12-17 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質封入マイクロゲルの作製 |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| CA3217914A1 (en) * | 2021-05-04 | 2022-11-10 | Kevin BRAY | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CA3227537A1 (en) * | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
| WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
| WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| IL322890A (en) * | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| US20250297006A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers |
| US20250376524A1 (en) * | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6290090A (en) * | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1874824A4 (en) * | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JP2014124186A (ja) | 2012-12-26 | 2014-07-07 | Industrial Technology Research Institute | 多価抗体フラグメントおよびその三量体化複合体 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| CN108601830B (zh) * | 2015-12-18 | 2023-02-03 | 比奥根Ma公司 | 双特异性抗体平台 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| WO2018178074A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
-
2020
- 2020-08-14 CN CN202080061412.XA patent/CN114302893B/zh active Active
- 2020-08-14 EP EP20761991.7A patent/EP4013797A1/en active Pending
- 2020-08-14 CA CA3147791A patent/CA3147791A1/en active Pending
- 2020-08-14 MX MX2022001942A patent/MX2022001942A/es unknown
- 2020-08-14 BR BR112022002012A patent/BR112022002012A2/pt unknown
- 2020-08-14 AU AU2020330063A patent/AU2020330063A1/en active Pending
- 2020-08-14 CN CN202510048366.4A patent/CN119954933A/zh active Pending
- 2020-08-14 WO PCT/US2020/046352 patent/WO2021030680A1/en not_active Ceased
- 2020-08-14 US US16/993,721 patent/US12077603B2/en active Active
- 2020-08-14 TW TW114123254A patent/TW202542199A/zh unknown
- 2020-08-14 KR KR1020227008242A patent/KR20220044821A/ko active Pending
- 2020-08-14 JP JP2022509082A patent/JP7629906B2/ja active Active
- 2020-08-14 TW TW109127674A patent/TWI890689B/zh active
-
2022
- 2022-02-02 IL IL290299A patent/IL290299A/en unknown
- 2022-04-08 US US17/716,830 patent/US12065508B2/en active Active
- 2022-10-17 US US17/967,418 patent/US11952430B2/en active Active
-
2024
- 2024-07-23 US US18/781,515 patent/US20240368312A1/en active Pending
-
2025
- 2025-02-03 JP JP2025015817A patent/JP2025072461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098732A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2018522541A5 (https=) | ||
| JP2019525738A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JPWO2019129221A5 (https=) | ||
| JP2022009816A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2018522888A5 (https=) | ||
| JPWO2020033702A5 (https=) | ||
| JPWO2021030680A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JPWO2021011885A5 (https=) | ||
| JPWO2020033587A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JPWO2020076992A5 (https=) | ||
| WO2018237341A1 (en) | A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY | |
| JPWO2022042488A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JPWO2021064137A5 (https=) | ||
| JPWO2022081516A5 (https=) | ||
| JPWO2022111425A5 (https=) |